Clinical Trial Update: Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I) [Phase 3]

View source ↗

Summary

A Phase 3 trial (REDUCTION-I) is evaluating tislelizumab with chemotherapy followed by surgery versus upfront surgery in resectable head and neck squamous cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Head and Neck Squamous Cell Carcinomas | Phase 3 | Status: RECRUITING